12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RFVIIIFc: Completed Phase II/III enrollment

Biogen Idec said at its analyst day that it completed enrollment in the open-label, international, pivotal Phase II/III A-LONG trial evaluating a low- and high-dose prophylaxis regimen of IV rFVIIIFc, and rFVIIIFc for use on demand in about 165 previously-treated hemophilia...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >